Metformin treatment examined for effects on aging-related gene expression in older adults with impaired glucose tolerance (pilot RCT).
This pilot randomized controlled trial investigated whether metformin treatment could restore gene expression patterns in older adults with impaired glucose tolerance to match those of younger healthy subjects. The study was motivated by preclinical evidence suggesting metformin may influence cellular aging processes beyond glucose control. No sample size, treatment duration, results, or effect sizes were reported in the available abstract.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: May 21, 2021 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Older adults with impaired glucose tolerance (IGT), compared to young healthy subjects
- Primary outcome
- Restoration of gene expression profile to that of young healthy subjects
- Effect size
- —
- Significance
- Not reported
- Journal
- Albert Einstein College of Medicine
- Published
- May 21, 2021
Sources
Primary source
- Albert Einstein College of Medicine ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.